[go: up one dir, main page]

MX2019004222A - Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias. - Google Patents

Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias.

Info

Publication number
MX2019004222A
MX2019004222A MX2019004222A MX2019004222A MX2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A MX 2019004222 A MX2019004222 A MX 2019004222A
Authority
MX
Mexico
Prior art keywords
dmpg
dmpc
egpg
lysopg
channelopathies
Prior art date
Application number
MX2019004222A
Other languages
English (en)
Inventor
Majeed Muhammed
Helson Lawrence
M Shopp George
Bouchard Annie
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/297,901 external-priority patent/US10449193B2/en
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of MX2019004222A publication Critical patent/MX2019004222A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención incluye composiciones y métodos para prevenir una o más canalopatías cardiacas o condiciones que resultan de irregularidades o alteraciones en los patrones cardiacos provocados por un agente activo o un fármaco en un sujeto humano o animal, que comprenden: una cantidad de un fosfatidilglicerol adaptado para administración oral efectiva para reducir o prevenir una o más canalopatías o condiciones cardíacas que resultan de irregularidades o alteraciones en patrones cardiacos provocados por el agente activo o fármaco y uno o más agentes organolépticos, tixotrópicos, o ambos organolépticos y tixotrópicos.
MX2019004222A 2016-10-19 2017-10-19 Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias. MX2019004222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/297,901 US10449193B2 (en) 2011-06-03 2016-10-19 Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
PCT/US2017/057446 WO2018075801A1 (en) 2016-10-19 2017-10-19 Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Publications (1)

Publication Number Publication Date
MX2019004222A true MX2019004222A (es) 2019-06-10

Family

ID=62019674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004222A MX2019004222A (es) 2016-10-19 2017-10-19 Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias.

Country Status (8)

Country Link
EP (1) EP3528848A4 (es)
JP (1) JP2019531309A (es)
KR (1) KR20190042775A (es)
CN (2) CN111481508A (es)
AU (2) AU2017345473A1 (es)
CA (1) CA3039596C (es)
MX (1) MX2019004222A (es)
WO (1) WO2018075801A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP4234037A3 (en) * 2017-10-19 2023-09-06 Signpath Pharma, Inc. Liquid compositions for peroral use comprising phosphatidylglycerol derivatives and thixotropic excipients for treating cardiac channelopathies caused by pharmacological agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20050233970A1 (en) * 2004-03-23 2005-10-20 Praecis Pharmaceuticals, Inc. Methods for treating long QT syndrome
WO2008093848A1 (ja) * 2007-02-02 2008-08-07 Sunstar Inc. ホスファチジルコリンを含有する炎症マーカー低減組成物
JP5638204B2 (ja) * 2009-05-29 2014-12-10 国立大学法人 岡山大学 経口投与用リポソーム製剤およびその製造方法
WO2012094033A1 (en) * 2011-01-05 2012-07-12 Livon Laboratories Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
US8753674B2 (en) * 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
CA2864475A1 (en) * 2012-02-16 2013-08-22 Vascular Biogenics Ltd. Methods for treating psoriasis and vascular inflammation
WO2014036534A1 (en) * 2012-08-31 2014-03-06 University Of North Texas Health Science Center Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy
WO2015187883A1 (en) * 2014-06-03 2015-12-10 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Also Published As

Publication number Publication date
CA3039596C (en) 2022-04-12
CA3039596A1 (en) 2018-04-26
CN109843331A (zh) 2019-06-04
EP3528848A4 (en) 2020-07-15
EP3528848A1 (en) 2019-08-28
WO2018075801A1 (en) 2018-04-26
AU2017345473A1 (en) 2019-04-18
JP2019531309A (ja) 2019-10-31
CN111481508A (zh) 2020-08-04
AU2020267307A1 (en) 2020-12-10
KR20190042775A (ko) 2019-04-24

Similar Documents

Publication Publication Date Title
MX2019005141A (es) Efecto protector de dmpc, dmpg, dmpc/dmpg, lisopg y lisopc contra fármacos que causan canalopatías.
EP3207931A3 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MY199027A (en) Method for treating or preventing ophthalmological conditions
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
JOP20190281A1 (ar) مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
IL274456A (en) Inhibitor of expression of pro-carcinogenic factors, screening method for an active ingredient thereof, expression cassette used in this method, diagnostic drug and diagnostic method
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
MX368734B (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
MX2019004222A (es) Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias.
HK1243704A1 (zh) 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2023007136A (es) Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que causan canalopatias.
MX2020010243A (es) Composiciones bucales y metodos para animales.
ZA202104167B (en) Compounds for use in the treatment of parkinson's disease